Is CG Oncology Inc (CGON) a risky stock?
As of July 30, 2026, Clavix grades CG Oncology Inc (CGON) B- for risk, a composite score of 65 out of 100 on an A+ to F scale, which puts CGON in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 30, 2026. Clavix regrades every trading day.
The five risk dimensions behind CGON's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how CGON scores on each, as of July 30, 2026.
What's moving CGON's risk right now
Company-specific signals Clavix flags behind CGON's current grade, drawn from recent news and filings as of July 30, 2026.
Kuehn Law is encouraging CGON investors to contact the firm, signaling an investigation that could lead to shareholder litigation and governance changes. The probe adds legal uncertainty that may weigh on the stock.
CGON's pivotal BOND-003 study showed durable responses, bladder preservation, and a favorable safety profile in high-risk BCG-unresponsive bladder cancer patients. Separately, traders bought a large volume of call options, a bullish options-market signal.
Recent CGON news
The latest headlines Clavix ingested for CG Oncology Inc, newest first. These feed the news-sentiment dimension of CGON's grade.
-
Kuehn Law, PLLC is investigating whether certain officers and directors of CG Oncology, Inc. (NASDAQ: CGON) breached their fiduciary duties to shareholders, with concerns over potential self-dealing.
-
EcoR1 Capital LLC increased its stake in CG Oncology (CGON) by 3.5% in Q1, acquiring additional shares to bring its total holdings to 1,102,000 shares, making CGON the fund's 8th largest position.
What a B- grade means
On the Clavix A+ to F scale, CGON's composite of 65 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell CGON or any security. Grades are risk indicators, not predictions of return. Data may be delayed.